Sebastian Klobuch
Overview
Explore the profile of Sebastian Klobuch including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1318
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Borgers J, Lenkala D, Kohler V, Jackson E, Linssen M, Hymson S, et al.
Nat Med
. 2025 Jan;
PMID: 39753970
New treatment approaches are warranted for patients with advanced melanoma refractory to immune checkpoint blockade (ICB) or BRAF-targeted therapy. We designed BNT221, a personalized, neoantigen-specific autologous T cell product derived...
2.
Pal S, Tran B, Haanen J, Hurwitz M, Sacher A, Tannir N, et al.
Cancer Discov
. 2024 Apr;
14(7):1176-1189.
PMID: 38583184
Therapeutic approaches for clear cell renal cell carcinoma (ccRCC) remain limited; however, chimeric antigen receptor (CAR) T-cell therapies may offer novel treatment options. CTX130, an allogeneic CD70-targeting CAR T-cell product,...
3.
Los C, Klobuch S, Haanen J
Cancer J
. 2024 Mar;
30(2):113-119.
PMID: 38527265
Major progress in prolonging survival of patients with advanced melanoma has been made in the past decade because of the development and approval of immune checkpoint inhibitor and targeted therapies....
4.
Klobuch S, Seijkens T, Schumacher T, Haanen J
Nat Rev Clin Oncol
. 2024 Jan;
21(3):173-184.
PMID: 38191921
Immunotherapy with immune-checkpoint inhibitors (ICIs) and targeted therapy with BRAF and MEK inhibitors have revolutionized the treatment of melanoma over the past decade. Despite these breakthroughs, the 5-year survival rate...
5.
Mackensen A, Haanen J, Koenecke C, Alsdorf W, Wagner-Drouet E, Borchmann P, et al.
Nat Med
. 2023 Oct;
29(11):2844-2853.
PMID: 37872225
The oncofetal antigen Claudin 6 (CLDN6) is highly and specifically expressed in many solid tumors, and could be a promising treatment target. We report dose escalation results from the ongoing...
6.
Klobuch S, Seijkens T, Haanen J
Chin Clin Oncol
. 2023 May;
12(2):19.
PMID: 37160670
In recent years, treatment with chimeric antigen receptor (CAR) T-cells has revolutionized the outcomes of patients with relapsed or refractory hematological malignancies with long-term remissions in >30% of patients. Similarly,...
7.
Rohaan M, Borch T, van den Berg J, Met O, Kessels R, Geukes Foppen M, et al.
N Engl J Med
. 2022 Dec;
387(23):2113-2125.
PMID: 36477031
Background: Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these patients will not have a durable benefit. Phase 1-2 trials...
8.
Klobuch S, Lim J, van Balen P, Kester M, de Klerk W, de Ru A, et al.
Proc Natl Acad Sci U S A
. 2022 Nov;
119(49):e2214331119.
PMID: 36442096
Human leukocyte antigen (HLA) molecules present small peptide antigens to T cells, thereby allowing them to recognize pathogen-infected and cancer cells. A central dogma over the last 50+ y is...
9.
Decking S, Bruss C, Babl N, Bittner S, Klobuch S, Thomas S, et al.
Int J Mol Sci
. 2022 Jun;
23(11).
PMID: 35682650
Accelerated glycolysis leads to secretion and accumulation of lactate and protons in the tumor environment and determines the efficacy of adoptive T cell and checkpoint inhibition therapy. Here, we analyzed...
10.
Laghmouchi A, Kester M, Hoogstraten C, Hageman L, de Klerk W, Huisman W, et al.
Front Immunol
. 2022 Mar;
13:831822.
PMID: 35251023
In the context of HLA-DP-mismatched allogeneic stem cell transplantation, mismatched HLA-DP alleles can provoke profound allo-HLA-DP-specific immune responses from the donor T-cell repertoire leading to graft-versus-leukemia effect and/or graft-versus-host disease...